[GlobeNewswire] - LEXINGTON, Mass. -- Agenus Inc. , a developer of therapeutic vaccines for cancer and infectious diseases, today announced it has completed patient screening in its Phase 2 randomized, double-blind, multicenter ...
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment